| Primary |
| Drug Use For Unknown Indication |
25.2% |
| Product Used For Unknown Indication |
18.6% |
| Diffuse Large B-cell Lymphoma |
14.7% |
| Rheumatoid Arthritis |
9.5% |
| B-cell Lymphoma |
7.6% |
| Non-hodgkin's Lymphoma |
5.9% |
| Chronic Lymphocytic Leukaemia |
4.9% |
| Mantle Cell Lymphoma |
3.1% |
| Lymphoma |
1.7% |
| Prophylaxis |
1.5% |
| Premedication |
1.4% |
| Hypertension |
1.1% |
| Hodgkin's Disease |
0.9% |
| Systemic Lupus Erythematosus |
0.8% |
| Malignant Lymphoid Neoplasm |
0.8% |
| Burkitt's Lymphoma |
0.7% |
| Pain |
0.5% |
| Immunosuppression |
0.3% |
| Diabetes Mellitus |
0.3% |
| Acute Lymphocytic Leukaemia |
0.3% |
|
| Febrile Neutropenia |
15.5% |
| Death |
12.5% |
| Thrombocytopenia |
7.9% |
| Vomiting |
6.8% |
| Pneumonia |
5.8% |
| Pyrexia |
5.8% |
| Sepsis |
5.5% |
| Progressive Multifocal Leukoencephalopathy |
5.0% |
| Neutropenia |
4.1% |
| Pulmonary Embolism |
4.1% |
| Weight Decreased |
3.4% |
| Respiratory Failure |
3.3% |
| Septic Shock |
3.0% |
| Urinary Tract Infection |
2.8% |
| Hepatitis B |
2.5% |
| Infection |
2.5% |
| Renal Failure |
2.5% |
| General Physical Health Deterioration |
2.3% |
| Myelodysplastic Syndrome |
2.3% |
| White Blood Cell Count Decreased |
2.3% |
|
| Secondary |
| Diffuse Large B-cell Lymphoma |
24.5% |
| Product Used For Unknown Indication |
12.5% |
| B-cell Lymphoma |
11.1% |
| Non-hodgkin's Lymphoma |
8.3% |
| Mantle Cell Lymphoma |
6.0% |
| Chronic Lymphocytic Leukaemia |
6.0% |
| Drug Use For Unknown Indication |
5.2% |
| Lymphoma |
4.3% |
| Prophylaxis |
4.2% |
| Burkitt's Lymphoma |
4.1% |
| Rheumatoid Arthritis |
3.7% |
| Burkitt's Leukaemia |
1.6% |
| Hypertension |
1.6% |
| Premedication |
1.5% |
| Malignant Lymphoid Neoplasm |
1.1% |
| Pain |
1.1% |
| Hodgkin's Disease |
1.0% |
| Constipation |
0.7% |
| Chemotherapy |
0.7% |
| Immunosuppression |
0.7% |
|
| Febrile Neutropenia |
8.5% |
| Pyrexia |
7.7% |
| Pneumonia |
6.7% |
| Neutropenia |
6.7% |
| Thrombocytopenia |
6.6% |
| Sepsis |
6.2% |
| Death |
6.2% |
| Myelodysplastic Syndrome |
6.1% |
| Infection |
5.6% |
| Vomiting |
5.3% |
| Hepatitis B |
4.5% |
| Progressive Multifocal Leukoencephalopathy |
4.2% |
| Pneumocystis Jiroveci Pneumonia |
4.2% |
| Weight Decreased |
3.9% |
| White Blood Cell Count Decreased |
3.4% |
| Septic Shock |
3.1% |
| Urinary Tract Infection |
3.0% |
| Pulmonary Embolism |
2.8% |
| Toxicity To Various Agents |
2.8% |
| Respiratory Failure |
2.6% |
|
| Concomitant |
| Idiopathic Thrombocytopenic Purpura |
18.1% |
| Product Used For Unknown Indication |
15.9% |
| Non-hodgkin's Lymphoma |
8.1% |
| Diffuse Large B-cell Lymphoma |
6.8% |
| Chronic Lymphocytic Leukaemia |
6.1% |
| Drug Use For Unknown Indication |
6.1% |
| B-cell Lymphoma |
5.9% |
| Rheumatoid Arthritis |
5.8% |
| Prophylaxis |
5.3% |
| Lymphoma |
3.8% |
| Chemotherapy |
3.6% |
| Mantle Cell Lymphoma |
3.0% |
| Renal Transplant |
2.1% |
| Infection Prophylaxis |
1.4% |
| Stem Cell Transplant |
1.4% |
| Hypertension |
1.4% |
| Premedication |
1.4% |
| Aplastic Anaemia |
1.4% |
| Bone Marrow Conditioning Regimen |
1.3% |
| Diffuse Large B-cell Lymphoma Refractory |
1.2% |
|
| Thrombocytopenia |
12.7% |
| Drug Ineffective |
10.6% |
| Pyrexia |
8.1% |
| Death |
7.9% |
| White Blood Cell Count Decreased |
7.4% |
| Therapeutic Response Decreased |
6.5% |
| Febrile Neutropenia |
4.8% |
| Neutropenia |
4.8% |
| Sepsis |
4.4% |
| Vomiting |
3.9% |
| Pneumonia |
3.8% |
| Myelodysplastic Syndrome |
3.8% |
| Rash |
3.4% |
| Platelet Count Decreased |
3.0% |
| Weight Decreased |
3.0% |
| Pancytopenia |
2.8% |
| Respiratory Failure |
2.4% |
| Neutrophil Count Decreased |
2.2% |
| Bone Marrow Failure |
2.1% |
| Progressive Multifocal Leukoencephalopathy |
2.1% |
|
| Interacting |
| Non-hodgkin's Lymphoma Unspecified Histology Aggressive |
39.6% |
| Product Used For Unknown Indication |
14.3% |
| Diarrhoea |
8.8% |
| Lymphoma |
8.8% |
| Non-hodgkin's Lymphoma |
8.8% |
| Chronic Lymphocytic Leukaemia |
5.5% |
| Diffuse Large B-cell Lymphoma |
4.4% |
| Immunosuppression |
3.3% |
| Mantle Cell Lymphoma |
3.3% |
| Thrombosis Prophylaxis |
3.3% |
|
| Lymphoma |
40.0% |
| Apnoea |
10.0% |
| Drug Interaction |
10.0% |
| International Normalised Ratio Increased |
10.0% |
| Agranulocytosis |
5.0% |
| Leukopenia |
5.0% |
| Muscle Haemorrhage |
5.0% |
| Neoplasm Progression |
5.0% |
| Neutropenia |
5.0% |
| Viral Mutation Identified |
5.0% |
|
